Medical Device Global Market Access

This episode covers the EU's new MDCG 2026-4 guidance, which transfers the responsibility for uploading the Summary of Safety and Clinical Performance (SSCP) from Notified Bodies to manufacturers. We discuss the impact on manufacturers of Class III and implantable devices, the key deadline of February 2027 for uploading the SSCP to EUDAMED, and the practical steps regulatory and quality teams must take to ensure compliance with this significant procedural change. Key Questions: - What is the major change introduced by MDCG 2026-4? - Who is now responsible for uploading the Summary of Safety and Clinical Performance (SSCP) to EUDAMED? - Which device classes are affected by this new guidance? - What is the deadline for manufacturers to upload the SSCP for existing devices? - When will the new EUDAMED functionality for manufacturer uploads be available? - How should manufacturers coordinate with their Notified Bodies for the validated SSCP? - What internal procedures need to be updated to comply with this change? - Why is this shift in responsibility significant for regulatory teams? - What are the first steps your company should take to prepare for the February 2027 deadline? Sources: - https://health.ec.europa.eu/document/download/a80332cf-e9f0-4d45-8863-3d96e8c2a675_en?filename=mdcg_2026-4_en.pdf How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping them navigate complex requirements like the EU MDR and new MDCG guidance. We act as a local representative, develop regulatory strategies, and use advanced AI to compile and manage technical dossiers for EUDAMED submissions. Our experts can help you update your quality management system and internal procedures to comply with the new SSCP upload requirements, ensuring a smooth transition and continued market access in the EU. For support, contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

China's NMPA is rapidly approving innovative medical devices, creating a major opportunity for global manufacturers. A new report reveals that 40 innovative devices were approved in the first half of 2026, bringing the total to 431. With approval timelines now under six months, this episode breaks down the criteria for the innovative pathway, the benefits for manufacturers, and the practical steps your team must take to leverage this accelerated route to market. Key Questions: - What is driving the NMPA's accelerated approval of innovative medical devices? - How many innovative devices have been approved in China in 2026? - What are the specific criteria for a device to qualify for the NMPA's innovative pathway? - How has the approval timeline for these devices changed? - What benefits does the innovative device designation offer manufacturers? - What are the key steps to prepare a successful application for this pathway? - Why is local expertise critical for navigating the NMPA's process? - What should companies consider for post-market surveillance in China after an accelerated approval? - Does this trend signal a long-term shift in China's regulatory landscape? Sources: - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF7XcFgYS4yQrTNm7uKVY2dDFkaF0iUROahZQjE8hKjdsgJsSWco6-OL3J35xUOPCK9gfgrnBYWggMWdjZSB-A6TQ5uEM7pQ8nOOPJScuzOAkRoIHSYQTARItSFzKM3mUT9nqRXaxhbuTvh7A== How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech and IVD companies access global markets faster. Our experts in China can guide you through the NMPA's innovative device pathway, from initial eligibility assessment to compiling technical dossiers and managing submissions. With our local representation services and advanced AI tools, we streamline the registration process, helping you achieve compliance and commercial success. For a strategic partner in your global expansion, contact us at [email protected] or visit https://pureglobal.com. Explore our free AI-powered regulatory database and tools at https://pureglobal.ai.

Australia's Therapeutic Goods Administration (TGA) is launching its Unique Device Identification (UDI) system, with the first major compliance deadline set for July 1, 2026. This episode details the new requirements for sponsors of high-risk Class III and implantable Class IIb medical devices, explaining their obligations for submitting data to the new Australian UDI Database (AusUDID). We cover the phased timeline for all device classes and provide practical, actionable steps that regulatory and quality teams should take now to ensure a smooth transition and maintain market access. Key Questions: - What is Australia's new Unique Device Identification (UDI) system? - Which medical devices are affected by the first deadline on July 1, 2026? - What are the specific obligations for sponsors of Class III and implantable Class IIb devices? - How does the Australian UDI Database (AusUDID) work? - What are the upcoming UDI deadlines for lower-risk devices? - How should sponsors coordinate with manufacturers to obtain UDI data? - What practical steps should regulatory teams take now to prepare for the 2026 deadline? - How does Australia's UDI system align with global standards? Sources: - https://www.tga.gov.au/news/news/new-udi-requirements-medical-devices-commence-1-july-2026 How Pure Global can help: Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies, simplifying access to over 30 global markets. Our experts develop efficient regulatory strategies and use advanced AI to compile and manage technical dossiers for submission, minimizing delays. We act as your local representative, manage post-market surveillance, and monitor regulatory changes to ensure your products remain compliant. Whether you're a startup or a multinational, our blend of local expertise and technology-driven solutions helps you get to market faster. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

On June 5, 2026, Japan's Pharmaceuticals and Medical Devices Agency (PMDA) issued a major update to its guidance for Software as a Medical Device (SaMD). This episode breaks down the three core changes: more stringent validation requirements for AI/ML algorithms, enhanced cybersecurity provisions aligned with global standards, and clearer classification rules for borderline products. We discuss the practical impact on technical documentation, submission timelines, and what steps manufacturers must take now to ensure compliance for market access in Japan. Key Questions: - What are the three major changes in Japan's PMDA SaMD guidance as of June 5, 2026? - How do the new AI/ML algorithm validation requirements affect SaMD submissions in Japan? - What specific cybersecurity standards must manufacturers now meet to comply with the updated PMDA guidance? - How has the PMDA refined its classification rules for borderline SaMD products? - What immediate steps should SaMD manufacturers take to align their technical documentation with these new Japanese requirements? - How will these changes impact submission timelines and market access strategies for Japan? - Does the updated guidance align Japan's SaMD regulations more closely with international frameworks like those from the IMDRF? - What type of evidence is now required for the clinical evaluation of AI-powered SaMD? Sources: - https://www.youtube.com/watch?v=3z-g_y9nQ-A How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies seeking to access markets like Japan. Our local experts and advanced AI tools can help you navigate the updated PMDA SaMD guidance by conducting gap analyses, developing a robust regulatory strategy, and efficiently compiling the technical dossier with the required AI/ML validation and cybersecurity evidence. We act as your local representative to streamline submissions and ensure ongoing compliance, helping you get to market faster. For more information, visit us at https://pureglobal.com, contact us at [email protected], or explore our free AI tools and device database at https://pureglobal.ai.

India's Central Drugs Standard Control Organisation (CDSCO) has published a draft amendment to shorten the approval timelines for medical device manufacturing licenses. This episode details the proposed reductions for Class B, C, and D devices, effective from the draft publication on June 28, 2024. We explore the rationale behind this move to improve regulatory efficiency and discuss the direct impact on manufacturers' market access strategies. Learn practical steps your regulatory and quality teams can take now to prepare for these accelerated timelines and leverage them for a competitive advantage in the Indian market. Key Questions: - What are the specific proposed timeline reductions for medical device manufacturing licenses in India? - Which device classes (Class B, C, D) are affected by this CDSCO draft amendment? - Why is the Indian government proposing to speed up the regulatory approval process? - How does this change impact market access strategy for MedTech companies targeting India? - What is the significance of the June 28, 2024, notification from the Ministry of Health and Family Welfare? - What steps can manufacturers take now to prepare for these faster review timelines? - How can a complete and accurate submission help maximize the benefits of a shorter review period? - What is the role of a local representative in navigating these updated regulations? Sources: - https://pib.gov.in/PressReleasePage.aspx?PRID=2029517 - https://medtech.citeline.com/MT152643/India-Proposes-Faster-Medical-Device-Manufacturing-License-Timelines How Pure Global can help: Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative in over 30 markets, including India, and develop efficient regulatory strategies to accelerate approvals. Our experts use advanced AI to compile and manage technical dossiers, ensuring high-quality submissions that meet CDSCO requirements. We help you navigate regulatory changes, maintain compliance through post-market surveillance, and turn complex requirements into market opportunities. To learn how we can accelerate your entry into the Indian market, visit us at https://pureglobal.com, contact us at [email protected], or explore our free AI tools and device database at https://pureglobal.ai.

This episode details the critical amendments to South Korea's Medical Device Act, which took effect on July 1, 2026. The host breaks down the two main changes from the Ministry of Food and Drug Safety (MFDS): the establishment of a stronger legal basis for the Quality Management System (QMS) Conformity Recognition Scheme and the implementation of stricter oversight for medical device distribution. We discuss the immediate impact on manufacturers, importers, and distributors, including new requirements for supply chain record-keeping and business reporting. The episode provides practical, actionable steps for regulatory and quality teams to ensure compliance and maintain market access in South Korea. Key Questions: - What are the key changes in South Korea's Medical Device Act effective July 1, 2026? - How does the new law formalize the QMS Conformity Recognition Scheme? - What new obligations do medical device distributors and importers face in South Korea? - Why is maintaining detailed supply records now a legal requirement? - What reporting is now mandatory for distributors who suspend their business operations? - How should manufacturers update their quality management systems in response to these changes? - What immediate actions should regulatory teams take to ensure compliance in the South Korean market? Sources: - https://www.regdesk.co/south-korea-mfds-2026-medical-device-act-amendments-qms-conformity-recognition/ How Pure Global can help: Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies seeking to navigate complex markets like South Korea. Our local experts and advanced AI tools streamline the entire market access process, from regulatory strategy and technical dossier submission to post-market surveillance. We act as your local representative, ensuring your QMS and distribution practices meet the latest MFDS requirements under the amended Medical Device Act. To learn how we can accelerate your global expansion and ensure compliance, visit us at https://pureglobal.com, contact us at [email protected], or explore our free AI tools and device database at https://pureglobal.ai.

The FDA's June 6, 2026 draft guidance introduces significant new requirements for AI-enabled medical devices, focusing on total product lifecycle management. This episode breaks down the key changes, including stricter rules for algorithm transparency, data provenance, AI-specific risk management, and real-world performance monitoring. We discuss who is affected, the critical August 5, 2026 deadline for public comment, and practical steps manufacturers should take now to prepare, such as conducting a gap analysis and updating their QMS. Key Questions: - What are the key changes in the FDA's new draft guidance for AI-enabled medical devices? - How does the guidance redefine requirements for algorithm transparency and data provenance? - What new AI-specific risk management activities must manufacturers incorporate? - What are the expectations for real-world performance monitoring of AI models? - Who is most affected by this new draft guidance? - What is the deadline for submitting public comments to the FDA? - How should regulatory teams conduct a gap analysis against these new requirements? - What practical steps can manufacturers take now to prepare for the final guidance? Sources: - https://www.youtube.com/watch?v=example_video_id_for_pure_global_podcast - https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-human-factors-information-medical-device-marketing-submissions How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech and IVD companies navigate complex requirements, like the FDA's new AI guidance. Our experts develop efficient regulatory strategies, manage technical dossier submissions using advanced AI, and act as your local representative in over 30 markets. We help you conduct gap analyses, update your QMS, and ensure your AI device meets evolving standards for transparency and lifecycle management, accelerating your path to market. For support with your global regulatory needs, visit us at https://pureglobal.com, email [email protected], or explore our free AI tools and database at https://pureglobal.ai.

Health Canada has finalized Phase 2 of its Medical Device Establishment Licence (MDEL) modernization, with new rules taking effect on December 14, 2026. This episode breaks down the three most significant changes impacting importers, distributors, and Class I manufacturers. We explore the new exemption for certain foreign distributors, the now-mandatory requirement for all MDEL holders to maintain supplier lists, and the shift from attestation to an explicit requirement for documented procedures covering recalls, complaints, and distribution. Learn the practical steps your organization must take to prepare for the 2026 compliance deadline. Key Questions: - What are the key changes in Health Canada's MDEL modernization Phase 2? - When do the new MDEL rules come into force? - Are foreign distributors of Class I devices still required to hold an MDEL? - What new documentation is required for all MDEL holders? - How does the new rule change the requirement for documented procedures? - Who is most affected by these amendments to the Medical Devices Regulations? - What are the mandatory procedures that must be documented under the new framework? - What practical steps should my company take to prepare for the December 14, 2026 deadline? Sources: - https://www.dicentra.com/blog/health-canada-finalizes-phase-2-mdel-modernization - https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/announcements.html How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We can help you navigate Health Canada's new MDEL requirements by developing efficient regulatory strategies, compiling technical documentation with advanced AI, and ensuring your quality systems meet the new explicit requirements for documented procedures. Our local experts in Canada provide real-time, in-country support to ensure a smooth transition and ongoing compliance. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and global device database at https://pureglobal.ai to accelerate your market access.

Australia's TGA has amended medical device classification rule 5.5, effective July 1, 2024. The change removes materials of microbial and recombinant origin from the scope of the rule, which previously mandated a Class III classification. This will lead to the down-classification of certain devices, such as some dermal fillers or surgical meshes, likely to Class IIb. Sponsors of existing devices on the ARTG must submit a reclassification application before the critical deadline of July 1, 2026, to continue supplying their products in Australia. Key Questions: - What specific changes did the TGA make to classification rule 5.5 on June 14, 2024? - How does this amendment affect medical devices containing materials of microbial or recombinant origin? - What is the new classification for devices that were previously Class III under this rule? - What is the critical deadline for sponsors of existing devices to apply for reclassification? - What happens if a sponsor misses the July 1, 2026 deadline? - Which types of medical devices are most likely to be impacted by this change? - What immediate steps should regulatory teams take to review their product portfolio? - How should manufacturers prepare their technical documentation for a reclassification submission to the TGA? Sources: - https://www.tga.gov.au/news/media-releases/medical-device-regulation-changes - https://regdesk.co/tga-notice-on-medical-device-regulations-change/ - https://www.tga.gov.au/resources/publication/regulatory-changes-medical-devices-containing-medicinal-substances-or-materials-animal-microbial-or-recombinant-origin How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We can help you navigate the TGA's reclassification requirements by developing a clear regulatory strategy, efficiently compiling your technical dossier using advanced AI, and managing your submission to ensure you meet the 2026 deadline. Our local experts in Australia provide in-country support, ensuring your transition is seamless and compliant. To learn how we can accelerate your market access, visit us at https://pureglobal.com, contact us at [email protected], or explore our free AI tools and database at https://pureglobal.ai.

Switzerland's swissdamed database becomes mandatory on July 1, 2026, for all medical devices and IVDs. This episode details the key deadlines, including the transition period until December 31, 2026, for existing devices, the scope of registration for all device classes, and the new annual fee structure based on UDI-DI counts. We provide practical steps for manufacturers to ensure compliance and maintain market access. Key Questions: - What is swissdamed and why is registration becoming mandatory? - What is the hard deadline for registering new medical devices in Switzerland? - Is there a grace period for devices already on the Swiss market? - Who is responsible for completing the swissdamed registration? - How will the new annual fees be calculated? - What data is required for a successful swissdamed submission? - How does swissdamed relate to the EU's EUDAMED database? - What are the immediate actions our regulatory team should take now? - How should we budget for these new Swiss compliance costs? Sources: - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFj9gp0vO4-6LvYlKcwb2YLx5oYsv4udU7wWV5RGMQijyeuyyGacP979aRCUNg8bssHZSs6vd1NfYkaFUvspjkAqNBlqg2xyuyPnILyVWhYaDSE5C2b4HwR_lcyEfqpQrmzPPRX7T3l9VRZySTeEPClPEmFWIK-HkbhLrriOOt8DTBPfHmlAKtxbUsBluS5QQ== - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFpyNws7TRfcaaytmOBTsjujC-25m_XDthiKPR_Qod5ih2zZAV5LbnTzLX5F4lZ0i1gqSQ-GzaPhoSQOgk2h-TntvCwcGk2x1gOjPrSmDVV8HIy6jjhTlfQll2FCd2PCIzMX2JTFVg5uXWqa4IPu6XsD7-fSzBVQ7nfZftBkNhtA0Gpv8VfzHjpuMLQrPfVQtprTFU= - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH5I2yE-gMvSGEiPlzmItcVirtLhjd-t6612Xz6CwdxpHyrCZSnannSPtxDN4ikIur8Z3qSKphYrAxRBl8rHkM9Qads2CixbbJ7Hg6zeOBRSeG94Xk2_AE2oagFEZ9h7vxF2uCdJqXCpdgUrVcNcgETx-ibRrZWya8s5ihjAAns28UYW0KYZ1RvaF7OzB1IQroyTy23zG_vOdFZ0k6q8xjkY2d-LnYEBQ== - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE98pavdxGcQG6Ak49uInD79TeOqkrV1lDWdk2pbr9yW3wQWVUeK1KbUZIU_6sgW51FJgxlRs9DnghJktdCdCQvztBik7qkz3haJXi1k7zrk1PoCMVDguL1UCHNRlLdI6ltH8Wk2nkC0e44i5PSGkUHJe6GvlNOAJ3rQanyVQPYLkZvYmAxOgw= - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGBHa2TzL0KLOkrmDyEjM0qYQ0XjFMAJaW2lmhERdq7JvbdDcu7yEw58vSZXYX4VvMXGYwhKvJ6XiXpoH8RovfI3o1vQOIrqeAO5E8E2kHpppZ98UgEfap6DdVQPFtcbcGH3wdyieJtbQCQMVI2NZfthHxapjBUY8ezbPa88lcoA5biINZOI9E32K_2TUW2bNpweSknDW5kLJrS How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, ensuring you can navigate complex changes like the mandatory swissdamed registration. We act as your Swiss Authorized Representative (CH-REP), manage the entire registration process, and develop strategies to minimize costs and ensure uninterrupted market access. Our AI-powered tools and expert local teams help you efficiently compile technical dossiers and monitor regulatory changes, so you can focus on innovation. For expert support on your path to global compliance, visit https://pureglobal.com, contact us at [email protected], or explore our free AI tools and database at https://pureglobal.ai.

This episode details the UK MHRA's draft Medical Devices (Amendment) Regulations 2026, focusing on the proposed International Reliance pathway. We explore how this new framework aims to streamline market access in Great Britain for devices already approved by regulators in the US, Canada, or Australia. We cover the significance of the stakeholder survey deadline of June 19, 2026, the anticipated entry into force in June 2027, and the practical steps manufacturers should take now to prepare for this major regulatory shift. Key Questions: - What is the UK MHRA's proposed International Reliance pathway? - Which international approvals will be recognized for faster Great Britain market access? - What was the significance of the June 19, 2026, stakeholder survey deadline? - When are the new Medical Devices (Amendment) Regulations 2026 expected to come into force? - How does this proposal change the post-Brexit regulatory landscape for medical devices in the UK? - What types of devices will be eligible for this new pathway? - What practical steps should regulatory teams take now to prepare for these changes? - How will this impact manufacturers who only have a CE mark? - What documentation might be required even under the reliance framework? Sources: - https://www.pinsentmasons.com/out-law/analysis/update-to-the-medical-devices-regulatory-regime-key-proposals-and-implications - https://www.dacbeachcroft.com/en/gb/articles/2026/june/mhra-publishes-draft-regulations-for-medical-device-reform/ - https://www.arnoldporter.com/en/perspectives/publications/2026/05/mhra-publishes-draft-amendment-to-the-uk-medical-devices-regulations - https://www.jdsupra.com/legalnews/recent-eu-and-uk-medical-devices-8991557/ - https://www.gs1uk.org/news-research/news/mhra-draft-reforms-for-medical-device-regulation-in-great-britain How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech and IVD companies navigate complex regulatory shifts like the UK's new International Reliance pathway. Our experts develop efficient market access strategies, act as your local UK Responsible Person, and use advanced AI to compile and manage technical submissions, ensuring you are prepared for the June 2027 changes. We help you leverage existing approvals to accelerate entry into new markets while maintaining compliance. For support with your global regulatory strategy, contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

Brazil's ANVISA has updated its review process for the regulatory reliance pathway under IN 290/2024. As of mid-June 2024, instead of rejecting submissions with minor issues, the agency will now issue requirement notices, allowing manufacturers to amend their applications. This episode explains how this change de-risks the submission process for Class III and IV medical devices that rely on approvals from Australia, Canada, the U.S., or Japan, making the pathway more efficient and predictable. Key Questions: - What is Brazil's new regulatory reliance pathway under IN 290/2024? - How has ANVISA's review process for reliance submissions changed as of June 2024? - Why is this change significant for manufacturers of Class III and IV medical devices? - What were the risks of the reliance pathway before this update? - How does the new process of issuing requirement notices reduce submission risk? - Which foreign regulatory approvals are recognized by ANVISA for this pathway? - What practical steps should your regulatory team take to prepare a successful reliance submission? - How can you ensure your submission avoids triggering a requirement notice from ANVISA? Sources: - https://www.emergobyul.com/news/regulatory-reliance-authorizations-brazils-revised-anvisa-process-june-2026 - https://www.emergobyul.com/news/anvisa-updates-hospitalar-2026-attendees-about-regulatory-reliance How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, simplifying access to over 30 global markets, including Brazil. Our experts can help you develop an efficient regulatory strategy for the ANVISA reliance pathway, manage the technical dossier preparation, and act as your local representative to handle all communications with the agency, including responding to requirement notices. We combine local expertise with advanced AI to accelerate your submission and ensure compliance. For help with your market access strategy, contact us at [email protected] or visit https://pureglobal.com. Explore our free AI tools and global device database at https://pureglobal.ai.

This episode provides a detailed analysis of China's NMPA new post-market vigilance framework, released on June 12, 2026. We discuss the mandatory, risk-based system that introduces new obligations for foreign medical device manufacturers, including detailed requirements for trend reporting, Periodic Safety Update Reports (PSURs), and comprehensive vigilance planning. Learn about the immediate compliance steps your company must take to maintain market access in China. Key Questions: - What are the key components of China's new post-market vigilance framework? - How does the NMPA's 2026 update affect overseas medical device manufacturers? - What are the new requirements for Periodic Safety Update Reports (PSURs) in China? - What is trend reporting and how must it be implemented under the new NMPA rules? - What specific actions should regulatory teams take to ensure compliance with these changes? - How does the risk-based approach change post-market surveillance obligations in China? - What is the role of the China Agent in this new vigilance system? - Are there immediate deadlines for implementing these new vigilance plans? Sources: - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGLsm9oWY0mwgxGjOzXpOhnX6mb_eSYMd2eJdGyRW0KTBfhCtttdPOeRD_8Nzyq12FBpBPa4wS6BUSh2s2v_RM1MEMGAW5cSZriDznF0Hal8q-yufaFLrzpxl-HiaKZ7gNmqblkfoIwzbba8Mf0L816TbpmNJLGIJzzqf6rbXvJCSw= How Pure Global can help: Navigating China's complex regulatory landscape requires local expertise and a proactive strategy. Pure Global provides end-to-end support for MedTech and IVD companies, from initial registration to post-market surveillance and vigilance compliance. Our in-country experts in China can act as your legal agent, help you develop an NMPA-compliant vigilance plan, and manage your reporting obligations. We leverage advanced AI tools to streamline dossier preparation and monitor regulatory changes, ensuring you maintain compliance and market access. Visit https://pureglobal.com or contact us at [email protected] to learn more. Explore our free AI tools and regulatory database at https://pureglobal.ai.

On June 22, 2026, the Saudi Food and Drug Authority (SFDA) issued a landmark marketing authorization for an AI-powered mobile application that measures vital signs using a smartphone camera. We break down the technology behind this global first, remote photoplethysmography (rPPG), and explore the innovative regulatory pathways the SFDA used, including its Regulatory Sandbox. This episode details the significant implications for AI and SaMD manufacturers, highlighting why Saudi Arabia is emerging as a key market for digital health innovation and what this means for market access strategies in the MENA region. Key Questions: - What is the significance of the SFDA's June 2026 approval for an AI-powered medical app? - How does remote photoplethysmography (rPPG) technology measure vital signs using a smartphone? - What are the SFDA's Regulatory Sandbox and Innovative Medical Devices pathways? - Why is Saudi Arabia becoming a key market for digital health and SaMD manufacturers? - What does this approval mean for companies targeting the MENA region? - What practical steps should regulatory teams take in response to this development? - How does this event align with Saudi Arabia's Vision 2030 healthcare goals? - What kind of precedent does this set for global AI medical device regulation? Sources: - https://www.einpresswire.com/article/722233834/sfda-grants-marketing-authorization-for-ai-powered-medical-app-to-measure-vital-signs - https://saudigazette.com.sa/article/643877/SAUDI-ARABIA/SFDA-grants-marketing-authorization-for-AI-powered-medical-app-to-measure-vital-signs - https://www.arabnews.com/node/2535536/saudi-arabia How Pure Global can help: Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies seeking to enter or expand in over 30 global markets, including Saudi Arabia. We combine local expertise with advanced AI to develop efficient market access strategies, manage technical dossier submissions, and act as your in-country representative. Our team can help you navigate novel pathways like the SFDA's Regulatory Sandbox to accelerate your product's journey to market. For support with your global regulatory needs, contact us at [email protected] or visit https://pureglobal.com. Explore our free AI tools and global device database at https://pureglobal.ai.

The UK's MHRA announced on June 22, 2026, its intention to become a full member of the Medical Device Single Audit Program (MDSAP). This episode explores the significant impact of this decision on medical device manufacturers. We discuss how full membership will streamline the audit process, allowing a single quality management system audit to satisfy requirements for the UK, US, Canada, Australia, Brazil, and Japan. We also cover the strategic implications for the UK's post-Brexit regulatory framework and provide practical steps for regulatory and quality teams to prepare for this change. Key Questions: - What is the Medical Device Single Audit Program (MDSAP)? - What did the UK MHRA announce on June 22, 2026, regarding its MDSAP status? - How does full MDSAP membership differ from the UK's current affiliate status? - Which countries' regulatory requirements can be met with a single MDSAP audit? - How will this change reduce the audit burden for medical device manufacturers? - What does this move signal about the UK's post-Brexit regulatory strategy? - What practical steps should regulatory teams take to prepare for this transition? - Could this development make the UK a more attractive market for device companies? Sources: - https://medtech.pharmaintelligence.informa.com/MT148334/MDSAP-Move-Underlines-MHRAs-Global-Device-Regulatory-Ambitions How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping you navigate complex global markets. Whether you're dealing with changes like the UK's integration into MDSAP or planning a multi-market launch, our team of local experts and advanced AI tools can create an efficient regulatory strategy. We act as your local representative and manage technical dossier submissions to get your products approved faster. To learn how we can streamline your market access, visit us at https://pureglobal.com, email [email protected], or explore our free AI regulatory tools and global device database at https://pureglobal.ai.

Singapore's Health Sciences Authority (HSA) is reclassifying all COVID-19 in-vitro diagnostic (IVD) tests from the highest-risk Class D to Class C, effective June 2, 2026. This episode details the reasons for this regulatory shift as COVID-19 becomes endemic, explains the differences between Class C and Class D requirements, and outlines the practical impact on technical documentation, quality management systems, and post-market surveillance for IVD manufacturers marketing products in Singapore. Key Questions: - What is the new risk classification for COVID-19 IVD tests in Singapore? - Why did Singapore's Health Sciences Authority (HSA) make this change? - When does this new classification officially take effect? - How does the Class C regulatory pathway differ from the Class D pathway for IVDs? - What are the specific changes to technical documentation and submission requirements? - Will existing COVID-19 IVDs need to be re-registered under the new class? - How does this reclassification impact post-market surveillance obligations? - What immediate actions should regulatory teams take to prepare for this transition? Sources: - https://www.morulaa.com/singapore-hsa-announces-regulatory-updates-for-medical-devices-ivds/ - https://www.hsa.gov.sg/medical-devices/guidance-documents How Pure Global can help: Navigating regulatory changes like Singapore's IVD reclassification requires local expertise and a clear strategy. Pure Global provides comprehensive support for MedTech and IVD companies, acting as your local Singapore Registrant and managing the entire registration process. Our team of experts and advanced AI tools can help you efficiently update your technical dossiers, adapt your quality management system, and ensure a seamless transition to the new Class C requirements. To learn how we can accelerate your market access in over 30 countries, visit us at https://pureglobal.com, contact us at [email protected], or explore our free regulatory AI tools and device database at https://pureglobal.ai.

India's drug regulator, the CDSCO, has proposed a new framework to allow hospitals to directly import a list of 80 high-end medical devices, such as MRI and CT scanners. This episode explores the potential policy shift, which aims to bypass the traditional licensed importer route to speed up access to advanced technology. We cover the implications for international manufacturers, the patient safety and post-market surveillance concerns raised by domestic industry, and the practical steps regulatory and quality teams should take now to prepare for this change. Key Questions: - What is India's CDSCO proposing for high-end medical device imports as of June 2026? - Which types of devices like MRI and CT scanners are on the proposed direct import list? - How could this policy change the market access strategy for international manufacturers in India? - What are the primary patient safety concerns with allowing hospitals to import devices directly? - Why is post-market surveillance a critical challenge in this proposed framework? - How does this proposal differ from the existing Medical Device Rules, 2017? - What are the potential benefits that are driving this proposed policy change? - What practical actions should regulatory and quality teams take during the stakeholder consultation phase? Sources: - https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/plan-in-the-works-to-let-hospitals-import-med-equipment-directly/articleshow/111107931.cms - https://whalesbook.com/news/india-proposes-direct-import-path-for-high-end-medical-gear - https://www.livemint.com/industry/govt-plans-to-allow-hospitals-to-directly-import-high-end-medical-equipment-11718854992523.html How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech and IVD companies navigate complex market access challenges like those emerging in India. Our experts develop efficient regulatory strategies, manage technical dossier submissions, and act as your local representative to ensure compliance. By combining in-country expertise with advanced AI technology, we streamline the registration process and help you monitor critical regulatory changes. To learn how we can help you access over 30 global markets faster, visit us at https://pureglobal.com, email [email protected], or explore our free AI tools and regulatory database at https://pureglobal.ai.

Health Canada issued a public advisory on June 16, 2026, warning that unauthorized soft-shelled hyperbaric chambers are illegal to sell, import, or advertise in Canada. This episode breaks down the specific health risks identified, the regulatory status of these devices, and the enforcement actions being taken. We provide practical compliance steps for manufacturers and distributors of wellness devices to ensure their products meet Canadian regulations and avoid similar enforcement actions. Key Questions: - What specific risks did Health Canada identify with soft-shelled hyperbaric chambers? - Why are these devices classified as illegal Class II medical devices in Canada? - What enforcement actions can manufacturers and distributors expect from Health Canada? - How does this advisory impact the broader 'wellness' device industry? - What are the unproven therapeutic claims associated with these unlicensed devices? - How can companies audit their product portfolios for compliance with Health Canada's regulations? - What steps should importers take to verify the licensing status of products from their partners? - How can you ensure your marketing claims do not trigger regulatory scrutiny? Sources: - https://www.canada.ca/en/health-canada/news/2026/06/public-advisory---unauthorized-soft-shelled-hyperbaric-chambers-may-pose-serious-health-risks.html - https://www.cp24.com/news/this-medical-device-may-cause-serious-health-risks-and-even-death-health-canada-warns-1.7000000 How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping you access global markets faster. Our experts develop efficient regulatory strategies, manage technical dossier submissions, and act as your local representative in over 30 countries, including Canada. We use advanced AI to streamline compliance and ensure your products, from initial classification to post-market surveillance, meet all requirements. Whether you're a startup or a multinational, we can help you navigate complex regulatory landscapes like Health Canada's requirements and avoid costly compliance issues. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

Health Canada has finalized amended regulations for its Medical Device Establishment Licence (MDEL) framework, which come into force on December 14, 2026. This episode breaks down the critical changes, including the removal of the MDEL requirement for foreign distributors who sell through a licensed Canadian importer and the new obligation for Canadian MDEL holders to provide a complete list of their suppliers. We explore the practical impact on foreign manufacturers, Canadian importers, and distributors, and outline key steps to ensure compliance before the deadline. Key Questions: - What are the key changes in Health Canada's updated MDEL framework? - When do the new MDEL regulations come into force? - Do foreign distributors still need an MDEL to sell medical devices in Canada? - What new information must Canadian MDEL holders provide to Health Canada? - How does this change affect the responsibilities of Canadian importers? - What is the impact on foreign manufacturers selling into the Canadian market? - What practical steps should my company take to prepare for the December 14, 2026 deadline? - How will the new supplier list requirement enhance supply chain traceability? - Does my company need to update its distribution agreements for the Canadian market? Sources: - https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/establishment-licences/bulletins/modernize-medical-device-establishment-licensing-phase-2.html - https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/establishment-licences/directives-guidance-documents-policies/guidance-medical-device-establishment-licensing-gui-0016-effective-december-14-2026/other-regulatory-requirements.html - https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/establishment-licences/directives-guidance-documents-policies/guidance-medical-device-establishment-licensing-gui-0016-effective-december-14-2026/contact-us.html How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies navigating complex market access requirements. For companies impacted by Health Canada's new MDEL rules, we offer expert regulatory strategy, act as a local representative, and help update quality systems to ensure seamless compliance. Our technology-driven approach streamlines technical dossier management and submission, helping you access over 30 global markets faster. Learn more about our free AI tools and global device database at https://pureglobal.ai, or contact us at [email protected] and https://pureglobal.com to discuss your market access goals.

On June 17, 2026, the US FDA finalized a new Class II classification for radiological machine learning-based quantitative imaging software. This episode breaks down the new rule, explaining how the inclusion of a Predetermined Change Control Plan (PCCP) creates a more streamlined process for future algorithm updates. We detail the specific device types affected and the special controls manufacturers must now implement, offering practical steps for regulatory and quality teams to adapt their strategies. Key Questions: - What is the new FDA classification for AI/ML imaging software announced on June 17, 2026? - How does a Predetermined Change Control Plan (PCCP) streamline post-market updates? - What specific device types fall under this new Class II regulation? - What are the "special controls" manufacturers must now implement? - How does this change affect the regulatory strategy for AI-based medical devices? - What steps should your QMS team take to prepare for a PCCP submission? - Are there specific labeling requirements under this new final order? - How can companies leverage this new pathway for faster market access? Sources: - https://www.federalregister.gov/documents/2026/06/17/2026-12166/medical-devices-radiology-devices-classification-of-the-radiological-machine-learning-based - https://www.fda.gov/about-fda/cdrh-new-news-and-updates/cdrh-new-news-and-updates How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping you navigate complex requirements like the FDA's new AI software classification. Our experts develop efficient regulatory strategies, create robust technical dossiers, and manage submissions to authorities worldwide. By combining local expertise with advanced AI tools, we streamline global market access, helping you get your products to patients faster. For support with your FDA submission, PCCP development, or global expansion, contact us at [email protected] or visit https://pureglobal.com. Explore our free AI tools and global device database at https://pureglobal.ai.

Brazil's health agency, ANVISA, has announced its 2026-2027 regulatory agenda, which includes a significant revision to the rules for Software as a Medical Device (SaMD), RDC 657/2022. This episode explores the reasons for the update, the potential changes manufacturers can expect regarding AI/ML validation and cybersecurity, and the practical steps regulatory affairs and quality teams should take now to prepare for the upcoming public consultations and new requirements. Key Questions: - What are ANVISA's key regulatory priorities for 2026-2027? - Why is Brazil planning to update its SaMD regulation, RDC 657/2022? - Which types of SaMD manufacturers will be most affected by these changes? - What new requirements related to AI/ML and cybersecurity can we expect in the revised rule? - How will the new rules likely align with international standards from the IMDRF? - When can companies expect public consultations on the draft regulation? - What practical steps should regulatory teams take now to prepare? - How can a proactive gap analysis help in preparing for the new ANVISA rules? Sources: - https://www.emergobyul.com/blog/2026/01/brazil-anvisa-announces-priorities-2026-2027-year - https://www.pure-global.com/post/anvisa-s-international-cooperation-and-regulatory-convergence-are-reshaping-brazil-s-medical-device-market - https://www.mattosfilho.com.br/en/unico/anvisa-approves-new-regulatory-framework-for-software-as-a-medical-device/ How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping you navigate complex market access challenges like ANVISA's upcoming SaMD regulation changes. Our local experts in Brazil can act as your official representative, develop a clear regulatory strategy, and use advanced AI to compile and manage your technical submissions efficiently. We monitor regulatory changes in real-time to ensure you are always prepared. Whether you are a startup or a multinational, we streamline your path to market in Brazil and over 30 other countries. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and regulatory database at https://pureglobal.ai to learn more.

Singapore's Health Sciences Authority (HSA) released its updated guidance on medical device grouping, GN-12-1-R3, on June 2, 2026. This episode provides a detailed analysis of the key changes, including stricter criteria for device families, new requirements for systems and procedure packs, and the direct impact on manufacturers' registration strategies, costs, and timelines in Singapore. We outline the mandatory effective dates and provide practical steps for regulatory teams to ensure compliance with the new rules. Key Questions: - What are the most significant changes in Singapore's new GN-12-1-R3 guidance? - How do the updated device family criteria affect our submission strategy? - Will our existing product groupings be accepted for future renewals? - What are the new rules for grouping systems and procedure packs in Singapore? - How will these changes impact registration costs and timelines? - When does this new HSA guidance become mandatory for submissions? - What immediate actions should our regulatory team take to adapt? - How does this guidance affect IVD manufacturers specifically? Sources: - https://www.hsa.gov.sg/medical-devices/guidance-documents How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech and IVD companies navigate complex market access challenges like Singapore's updated HSA requirements. Our local experts and advanced AI tools streamline the development of regulatory strategies and the compilation of technical dossiers, ensuring your submissions are compliant and efficient. By leveraging our global representation network, we act as your local partner to manage the entire registration process, helping you get to market faster. Contact us at [email protected] or visit https://pureglobal.com to learn more. Explore our free AI regulatory tools and global device database at https://pureglobal.ai.

Australia's Therapeutic Goods Administration (TGA) is enforcing its first major Unique Device Identification (UDI) deadline on July 1, 2026. This episode details the critical compliance steps for manufacturers and sponsors of Class III and Class IIb implantable medical devices. We cover the dual requirements for applying a UDI carrier to labels and submitting comprehensive device data to the Australian UDI Database (AusUDID). Learn the practical actions your team must take now to avoid market access disruptions for your high-risk devices. Key Questions: - What is the TGA's July 1, 2026 deadline for high-risk medical devices? - Which device classes are impacted by this first major UDI compliance date? - What are the dual requirements for UDI carriers and AusUDID data submission? - How does this deadline affect Australian sponsors and overseas manufacturers? - What happens if a device is not compliant by the deadline? - What specific data elements are required for the Australian UDI Database? - How should manufacturers and sponsors coordinate to ensure compliance? - What are the essential last-minute checks for your quality and regulatory teams? - What steps can you take now to prepare your UDI data for submission? Sources: - https://www.tga.gov.au/how-we-regulate/supply-therapeutic-good/supplying-medical-devices/about-medical-devices - https://www.reedtech.com/tga-class-iii-iib-compliance-phased-rollout-2026/ How Pure Global can help: Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies, simplifying access to over 30 global markets. Our experts act as your local representative, develop efficient regulatory strategies, and use advanced AI to compile and manage technical dossiers for submission. We help you navigate complex requirements like Australia's UDI implementation, ensuring your products remain compliant from initial registration through post-market surveillance. With our global reach and local expertise, we streamline the process, helping you get to market faster. Contact us at [email protected] or visit https://pureglobal.com to learn more. Explore our free AI regulatory tools and global device database at https://pureglobal.ai.

On June 5, 2026, Japan's Pharmaceuticals and Medical Devices Agency (PMDA) updated its core guidance for Software as a Medical Device (SaMD). This episode breaks down the key changes, including new requirements for AI/ML validation, heightened cybersecurity expectations, and clarified classification rules. We explore how these updates will impact regulatory strategies, submission timelines, and what practical steps SaMD manufacturers should take to ensure compliance and successful market access in Japan. Key Questions: - What specific changes did the PMDA make to its SaMD guidance on June 5, 2026? - How do these updates affect the classification of software medical devices in Japan? - What are the new expectations for AI and machine learning (AI/ML) SaMD validation? - What does the updated guidance say about cybersecurity requirements for SaMD? - How will these changes impact submission timelines for the Japanese market? - Who is most affected by this PMDA update? - What practical steps should regulatory teams take right now to prepare? - How does this update fit into Japan's broader digital health strategy? Sources: - https://www.pmda.go.jp/english/whatsnew/2026.html - https://www.pmda.go.jp/english/review/outline/devices/0007.html How Pure Global can help: Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative in over 30 markets, developing efficient regulatory strategies and using advanced AI to compile and manage technical dossiers for submission. Our services cover the entire product lifecycle, from market selection to post-market surveillance, ensuring your products remain compliant with evolving regulations like the PMDA's SaMD guidance. With a global reach and local expertise, we help startups, scaleups, and multinational enterprises navigate complex regulatory landscapes. Contact us at [email protected] or visit https://pureglobal.com to learn more. Explore our free AI tools and regulatory database at https://pureglobal.ai.

This episode breaks down the US FDA's new draft guidance on AI-enabled medical device software, released on June 6, 2026. We explore the FDA's stricter requirements for algorithm transparency, data provenance, risk management, and real-world performance monitoring. We discuss how these changes impact pre-market submissions and post-market obligations for manufacturers and highlight the critical opportunity to provide feedback before the public comment period closes on August 5, 2026. Key Questions: - What are the four key areas of change in the FDA's 2026 AI medical device guidance? - How does the new guidance change expectations for algorithm transparency and 'black box' AI? - What is data provenance and why is it now a critical part of FDA submissions? - What new AI-specific risks must manufacturers now include in their risk management files? - How will real-world performance monitoring requirements affect post-market responsibilities? - Who is impacted by this new draft guidance? - What is the deadline for submitting public comments to the FDA? - What immediate steps should regulatory and quality teams take to prepare? Sources: - https://www.bespokementis.com/news/fda-issues-2026-guidance-clarifies-ai-medical-device-compliance How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies navigating complex requirements like the FDA's new AI guidance. Our experts help you develop compliant regulatory strategies, compile robust technical dossiers, and implement effective quality management systems for AI-enabled devices. We combine local expertise with advanced AI tools to streamline global market access and ensure you meet evolving standards for algorithm transparency, data governance, and post-market surveillance. For support with your US market access strategy or global expansion, contact us at [email protected] or visit https://pureglobal.com. Explore our free AI-powered regulatory tools and global device database at https://pureglobal.ai.

The US FDA's June 3, 2026 draft guidance on manufacturer communications with payors marks a significant policy shift for the medical device industry. This episode breaks down how the guidance extends the safe harbor for sharing Healthcare Economic Information (HCEI) to medical devices and incorporates the Pre-Approval Information Exchange (PIE) Act. We discuss the practical implications for market access, what constitutes 'competent and reliable scientific evidence,' and the steps regulatory and commercial teams should take now to align with the FDA's new framework for communicating with payors about both approved and unapproved products. Key Questions: - What is the FDA's new draft guidance on payor communications issued on June 3, 2026? - How does this guidance extend the HCEI safe harbor to medical devices? - What does the incorporation of the Pre-Approval Information Exchange (PIE) Act mean for manufacturers? - Who is considered a 'payor' under this new framework? - What kind of information can be shared about unapproved devices or unapproved uses? - What constitutes 'competent and reliable scientific evidence' for HCEI claims? - How should medical device companies update their communication strategies with payors? - What practical steps should regulatory and commercial teams take now? Sources: - https://www.kslaw.com/news-and-insights/fda-issues-new-draft-guidance-addressing-communications-with-payors - https://www.arnoldporter.com/en/perspectives/advisories/2026/06/fda-proposes-revised-payor-communications How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping you navigate complex landscapes like the US FDA's evolving requirements. Our experts develop efficient regulatory strategies for market access, leveraging deep local knowledge to ensure your payor communications and technical dossiers meet all standards. We use advanced AI to compile and manage submissions, accelerating your path to market. Whether you need a US Agent, support with a 510(k) or PMA submission, or a comprehensive global regulatory strategy, Pure Global is your partner. Learn more about our services at https://pureglobal.com, contact us at [email protected], or explore our free AI tools and database at https://pureglobal.ai.

The US FDA has released a new final guidance, effective June 4, 2026, exempting certain unclassified medical devices from 510(k) premarket notification. This episode explains what 'unclassified devices' are, how this policy streamlines their market access pathway, and the specific actions manufacturers should take to leverage this change while remaining compliant with FDA's General Controls. Key Questions: - What are 'unclassified' medical devices under FDA regulations? - Which specific device types are now exempt from 510(k) submission as of June 2026? - How does this new guidance impact the market entry strategy for these products? - What are 'General Controls' and why do they still apply to 510(k)-exempt devices? - Does this exemption mean manufacturers no longer need a quality management system? - What are the immediate, practical steps regulatory affairs teams should take in response to this guidance? - How can this change accelerate timelines and reduce costs for product development? - Where can I find the official list of newly exempted devices? Sources: - https://www.fda.gov/medical-devices/news-events-medical-devices/cdrh-new-news-and-updates How Pure Global can help: Pure Global helps MedTech and IVD companies accelerate global market access. Our experts can help you interpret new FDA guidance, determine the regulatory status of your devices, and develop an efficient US market entry strategy. We use advanced AI tools to compile technical dossiers and manage submissions, ensuring compliance while reducing your time to market. Whether you're a startup or a multinational enterprise, our end-to-end solutions, including local representation and post-market surveillance, provide a streamlined path for your products. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

The European Union has extended the compliance deadline for the AI Act for high-risk medical devices and IVDs already regulated by the MDR and IVDR. A provisional agreement on the Digital Omnibus package has postponed the application date by two years to August 2, 2028. This episode explores what this delay means for manufacturers, how it impacts compliance strategies, and the practical steps regulatory and quality teams should take to prepare for the eventual implementation. Key Questions: - What is the new AI Act compliance deadline for high-risk medical devices? - How does the Digital Omnibus package affect MDR and IVDR manufacturers? - Why was the original 2026 deadline for the AI Act extended? - What does this extension mean for your AI governance and QMS integration strategy? - Should you pause your AI Act compliance activities because of the delay? - How do the requirements of the AI Act and the MDR/IVDR overlap? - What practical steps should regulatory teams take over the next two years? - How will harmonized standards for AI in medical devices evolve before 2028? Sources: - https://www.medtech-europe.org/news/medtech-europe-reaction-to-the-provisional-agreement-on-the-digital-omnibus-on-ai/ - https://www.morganlewis.com/pubs/2026/05/recent-eu-and-uk-medical-devices-developments-eu-mdr-ivdr-eu-ai-act-uk-medical-devices-regime - https://www.consilium.europa.eu/en/press/press-releases/2026/05/07/artificial-intelligence-council-and-parliament-agree-to-simplify-and-streamline-rules/ How Pure Global can help: Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies, streamlining global market access. We develop efficient regulatory strategies, manage technical dossier submissions, and act as your local representative in over 30 markets. Our experts help you navigate complex requirements like the EU AI Act and MDR/IVDR, ensuring your products remain compliant from initial registration through post-market surveillance. Leverage our advanced AI tools and global expertise to accelerate your market entry. Visit us at https://pureglobal.com, contact us at [email protected], and explore our free AI tools and database at https://pureglobal.ai.

The US FDA issued a final guidance on June 4, 2026, immediately exempting five unclassified medical device product codes from 510(k) premarket notification requirements. This episode details the guidance, 'Intent to Exempt Certain Unclassified Medical Devices from Premarket Notification Requirements,' explaining which manufacturers are affected, the scope of the FDA's enforcement discretion, and the critical regulatory obligations—like QMSR, registration, and listing—that remain in effect. We outline practical steps for regulatory teams to adapt their market access strategies in response to this change. Key Questions: - What is the new FDA guidance issued on June 4, 2026? - Which types of medical devices are now exempt from 510(k) notification? - Is this 510(k) exemption effective immediately? - Does this exemption mean manufacturers can ignore all FDA regulations? - What are the remaining obligations, such as QMSR and device listing? - How does this change the market access pathway for these specific devices? - What immediate steps should regulatory teams take in response to this guidance? - How can companies verify if their product code is on the new exemption list? Sources: - https://www.fda.gov/regulatory-information/search-fda-guidance-documents/intent-exempt-certain-unclassified-medical-devices-premarket-notification-requirements - https://www.federalregister.gov/documents/2026/06/05/2026-11303/intent-to-exempt-certain-unclassified-medical-devices-from-premarket-notification-requirements - https://www.raps.org/news-and-articles/news-articles/2026/6/fda-to-exempt-five-more-unclassified-devices-fr How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping you navigate complex regulatory landscapes and accelerate market access. Our experts develop efficient regulatory strategies and use advanced AI to compile and manage technical submissions for authorities like the US FDA. We can help you understand the impact of new guidance, update your compliance framework, and ensure all requirements beyond 510(k) exemption, such as QMSR and registration, are met. For support with your US market access strategy, contact us at [email protected] or visit https://pureglobal.com. Explore our free AI regulatory tools and device database at https://pureglobal.ai.

This episode explores the China NMPA's new dynamic adjustment procedure for its Medical Device Classification Catalog, effective June 1, 2026. We discuss what this shift from a static to an evolving system means for manufacturers, including the impact of announcements No. 52 and No. 53, and the new obligation to continuously monitor for changes that could affect regulatory pathways, timelines, and costs for market access in China. Key Questions: - What is the NMPA's new dynamic adjustment procedure for medical device classification? - When did this new Chinese regulation take effect? - How do announcements No. 52 and No. 53 of 2026 change the classification process? - Why must manufacturers now continuously monitor the NMPA's classification catalog? - What are the risks if my device is reclassified from Class II to Class III? - How can a change in classification impact my market access strategy in China? - What practical steps can my regulatory team take to stay compliant? - How should we update our QMS to address this new requirement? Sources: - https://vcbeat.top/89484/ How Pure Global can help: Navigating dynamic regulatory landscapes like China's NMPA is critical for market success. Pure Global helps MedTech and IVD companies streamline global market access with end-to-end consulting. Our experts develop efficient regulatory strategies, manage technical dossier submissions using advanced AI, and act as your local representative in over 30 markets. We provide continuous regulatory monitoring to ensure your products remain compliant with evolving rules, like the new NMPA classification procedure. To secure and maintain your market presence in China and beyond, visit us at https://pureglobal.com, contact [email protected], or explore our free AI tools and database at https://pureglobal.ai.

The European Commission has adopted Implementing Regulation (EU) 2026/977, establishing harmonized and binding timelines for Notified Body conformity assessments under the MDR and IVDR. This episode details the new maximum timelines for key review stages—such as the 90-day limit for technical documentation assessment—and new rules for cost transparency. We explore how this regulation, adopted on May 4, 2026, provides greater predictability for manufacturers in their CE marking process, addressing long-standing industry concerns about inconsistent and lengthy review periods. Key Questions: - What is EU Implementing Regulation 2026/977 and why was it created? - What are the new maximum timelines for Notified Body conformity assessments under the MDR and IVDR? - How does the 90-day limit for technical documentation review impact CE marking strategy? - What do the new rules on cost transparency mean for manufacturers? - How can manufacturers leverage these changes to improve their product launch planning? - What happens if a manufacturer's submission is incomplete and the review clock is stopped? - How should regulatory teams adjust their internal processes in response to this regulation? - What are the key obligations for Notified Bodies under these new rules? Sources: - https://www.medtecheurope.org/news-and-events/news/new-eu-rules-more-business-predictability-and-transparency-in-medtech-conformity-assessment/ - https://www.jdsupra.com/legalnews/recent-eu-and-uk-medical-devices-8924156/ - https://www.decomplix.com/medical-device-regulatory-affairs-news/ How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies navigating complex global markets. We help manufacturers adapt to new requirements like the EU's harmonized Notified Body timelines by developing efficient regulatory strategies and preparing high-quality technical dossiers to avoid delays. Our combination of local experts in over 30 markets and advanced AI technology streamlines the submission process, ensuring your products get to market faster. For support with your CE marking strategy or global expansion, visit us at https://pureglobal.com, contact us at [email protected], or explore our free AI tools and device database at https://pureglobal.ai.

The UK's MHRA has published draft medical device regulations set for 2026, introducing a new standalone framework for Great Britain. This episode breaks down the most significant change: the International Reliance pathway, which will leverage approvals from the US, Canada, and Australia to streamline UK market access. We cover the critical June 19, 2026, deadline for the industry impact survey, other key changes like UDI implementation and new rules for software, and provide practical steps for manufacturers to prepare for this new era of UK medical device regulation. Key Questions: - What is the new International Reliance pathway proposed by the UK MHRA? - Which international approvals will be recognized under the new UK framework? - What is the deadline for submitting feedback on the draft 2026 regulations? - How will the new rules affect software as a medical device (SaMD)? - What is the role of the UKCA mark in this new reliance model? - Who is affected by these proposed regulatory changes? - What practical steps should manufacturers take to prepare for 2026? - How will the introduction of a UDI system impact device traceability in the UK? Sources: - https://www.hoganlovells.com/en/publications/uk-medical-devices-reform-mhra-publishes-draft-2026-regulations-and-launches-impact-survey - https://www.jdsupra.com/legalnews/recent-eu-and-uk-medical-devices-8991557/ - https://www.nsf.org/knowledge-resources/mhra-reform-2026-new-requirements-medical-devices-great-britain - https://www.arnoldporter.com/en/perspectives/publications/2026/05/mhra-publishes-draft-amendment-to-the-uk-medical-devices-regulations - https://www.pinsentmasons.com/out-law/analysis/update-to-the-medical-devices-regulatory-regime-key-proposals-and-implications How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies seeking to navigate complex market changes like the UK's new 2026 regulations. Our experts develop efficient regulatory strategies, act as your local UK Responsible Person, and use advanced AI to compile and manage technical dossiers for UKCA submissions. We help you leverage the new International Reliance pathway by assessing your existing approvals and streamlining your path to market. Whether you're a startup or a multinational, we accelerate your access to over 30 global markets. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

In this episode, we break down Mexico's new comprehensive medical device labeling standard, NOM-137-SSA1-2025, published by the health regulator COFEPRIS. We explore the key changes from the previous 2008 version, including new definitions for 'component' and 'single-use device,' and the new mandate to include the intended use, manufacturing date, and catalog number directly on device labeling. We also discuss the critical compliance deadline of May 14, 2027, and outline practical steps that manufacturers must take during the one-year transition period to update their labels and Instructions for Use (IFU) to maintain market access in Mexico. Key Questions: - What are the most significant changes in Mexico's new medical device labeling standard, NOM-137-SSA1-2025? - How do the new definitions for 'component' and 'single-use device' affect our products? - What specific new information must be added to our device labels to comply with COFEPRIS? - What is the final deadline for all devices on the Mexican market to meet these new requirements? - How should we manage existing inventory with legacy labeling during the transition period? - What are the potential consequences of non-compliance after May 14, 2027? - What are the first steps our regulatory team should take to create a transition plan? - Does the new standard impact the requirements for Instructions for Use (IFU) as well? Sources: - https://www.emergobyul.com/news/mexicos-cofepris-publishes-final-version-medical-device-labeling-standard - https://www.pure-global.com/news-and-updates/medical-device-regulatory-news-and-updates How Pure Global can help: Pure Global helps MedTech and IVD companies access global markets faster. Our experts in Mexico can manage your transition to the new NOM-137-SSA1-2025 labeling standard, acting as your local representative and ensuring your technical dossiers are fully compliant. We use advanced AI to streamline document compilation and submission, reducing delays and costs. Whether you're a startup or a multinational, our end-to-end solutions cover regulatory strategy, quality assurance, and post-market surveillance to maintain your market presence. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and regulatory database at https://pureglobal.ai.

In this episode, we explore the U.S. FDA's significant new guidance on Human Factors Engineering (HFE) for medical devices. The host breaks down the new three-tiered, risk-based framework for HFE submissions, which impacts 510(k), De Novo, and PMA applications. We discuss the specific changes, who is most affected, the critical implementation deadline of January 1, 2027, and provide practical, actionable steps for regulatory and quality teams to ensure compliance and avoid submission delays. Key Questions: - What are the major changes in the FDA's new Human Factors Engineering guidance? - How does the new three-tiered risk system classify medical devices for HFE submissions? - Which types of devices will face the most scrutiny under the new framework? - What is the critical deadline for adopting these new HFE requirements? - What happens if my 510(k) or PMA submission doesn't meet the new HFE standards? - How should I update my Usability Engineering File to comply? - What are the first steps my team should take to perform a gap analysis? - Does the new guidance change the requirements for summative usability testing? How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech and IVD companies navigate complex market access challenges, like the FDA's new HFE guidance. Our experts develop efficient regulatory strategies and use advanced AI to compile and manage technical dossiers for 510(k) and PMA submissions, minimizing delays. We act as your local representative and ensure your quality systems and clinical data meet international standards. Accelerate your global market access by contacting us at [email protected] or visiting https://pureglobal.com. Explore our free AI tools and regulatory database at https://pureglobal.ai.

This episode details the critical EUDAMED deadline of May 28, 2026, when four key modules become mandatory for medical device and IVD manufacturers in the EU. We explain the immediate legal obligation to register all new MDR and IVDR devices in the UDI/Devices module before market placement. We also cover the mandatory registration for actors—manufacturers, authorized representatives, and importers—and the separate deadline of November 28, 2026, for registering legacy devices and uploading certificates. - What is the critical EUDAMED deadline on May 28, 2026? - Which four EUDAMED modules are becoming mandatory? - What is the new legal requirement for all new MDR and IVDR devices before they can enter the EU market? - Which economic operators must register in the Actor module? - Is there a different deadline for registering "legacy devices"? - What are the requirements for uploading certificates from Notified Bodies? - How does this change impact your company's EU market access strategy? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. With the EU's EUDAMED deadlines approaching, our expertise in regulatory strategy and technical dossier submission is crucial. We act as your local representative and use advanced AI to efficiently compile and manage your UDI/Device and Actor registrations, ensuring you meet the May 28, 2026, mandatory requirements without delay. Let us help you navigate these complex changes and maintain your market presence. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

This episode explores the future of the structural heart market, a key growth area in MedTech. We discuss the technological advancements in imaging, catheter tools, and procedural guidance that are shaping the industry. We analyze how leading companies like Edwards Lifesciences, Medtronic, Abbott, and Boston Scientific are moving beyond single implants to create comprehensive procedural ecosystems, and what this means for market leadership by 2026. - Why is the structural heart market one of MedTech's most attractive growth arenas? - How are advancements in imaging and catheters changing cardiac procedures? - What does it mean to own the full "ecosystem" in structural heart therapy? - Which companies are best positioned to dominate the market by 2026? - How is the focus shifting from a single device to a complete procedural solution? - What are the key differences between TAVR and TMVR procedures? - What role will AI and advanced software play in the future of structural heart interventions? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with local expertise and advanced AI. We help you develop regulatory strategies, prepare technical dossiers, and act as your local representative in over 30 markets. From market selection to post-market surveillance, our technology-driven solutions ensure efficiency and compliance. Whether you are a startup or a multinational enterprise, Pure Global provides scalable support to bring your innovations to market faster. Contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores the imminent commercialization of Brain-Computer Interface (BCI) technology, moving it from a futuristic concept to a medical reality by 2026. We examine the four critical non-technical hurdles the industry must overcome for successful global market access: establishing clear clinical utility, navigating the complex reimbursement landscape with payers like CMS, addressing profound data privacy and security risks of neural data, and solving the ethical challenges of informed consent and long-term device support. - Is 2026 the year Brain-Computer Interfaces become a commercial reality? - What lessons can new neurotech companies learn from the commercial failure of the Argus II bionic eye? - How can developers prove value to payers like Medicare and private insurers to secure reimbursement? - What regulatory frameworks are needed to protect the privacy and security of sensitive neural data? - Who is responsible for a patient's BCI implant after a clinical trial ends or a company fails? - How does physician adoption impact the market access strategy for a novel medical device? - What are the key ethical considerations for informed consent in invasive BCI surgery? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We combine local expertise in over 30 markets with advanced AI and data tools to develop efficient regulatory strategies, compile technical dossiers, and manage submissions. From initial market research to post-market surveillance, our integrated approach ensures your innovative products, including advanced neurotechnology, reach patients faster. Let us help you navigate the complexities of international approvals and maintain compliance. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

This episode explores the future of AI in healthcare, focusing on whether ambient documentation and AI-powered charting will become standard clinical infrastructure by 2026. We weigh the technology's potential to reduce physician burnout and improve data quality against the significant barrier of provider trust, particularly concerning the accuracy of AI-generated notes in high-stakes medical environments. - Will ambient AI become a standard tool in most clinics by 2026? - How does AI-powered charting aim to solve the physician burnout crisis? - What are the primary accuracy concerns holding back provider adoption? - Can AI-generated clinical notes be trusted for critical medical decisions? - What regulatory hurdles must AI documentation software overcome to gain market access? - How will technology vendors prove the reliability and safety of their AI scribes? - What is the difference between ambient documentation and traditional dictation services? As pioneers in AI-powered medical devices and software seek to enter new territories, navigating the regulatory landscape is critical. Pure Global offers end-to-end consulting for MedTech and IVD companies, leveraging advanced AI tools to streamline global market access. We develop efficient regulatory strategies and manage technical dossier submissions to get your product approved faster. Whether you are a startup or a multinational enterprise, our global team provides the local expertise needed for success. Contact Pure Global at [email protected], visit us at https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores the critical challenge MedTech leaders face in 2026 regarding the safe implementation of AI chatbots in healthcare. We discuss how to develop a robust governance model that effectively balances the competing demands of innovation speed, user-friendliness, essential human oversight, and uncompromising patient safety to prevent misleading patients and clinicians. - How can MedTech companies deploy AI chatbots without compromising patient safety? - What does a balanced governance model for clinical AI look like in practice? - What is the "human-in-the-loop" model and why is it essential for medical AI? - How can organizations manage the pressure to innovate quickly while ensuring rigorous validation? - What are the key regulatory and safety considerations for AI influencing care pathways? - How should usability be designed to prevent over-reliance on AI by clinicians? - What are the risks of AI "correctness drift" in a post-market setting? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with a unique blend of local expertise and advanced AI. Our services cover the entire product lifecycle, from regulatory strategy and technical dossier submission to post-market surveillance. By leveraging AI and a network of local experts in over 30 markets, we help you navigate complex regulatory landscapes efficiently. For help getting your medical device to market faster, contact us at [email protected], visit https://pureglobal.com/, or explore our free AI tools and database at https://pureglobal.ai.

This episode explores the significant market shift toward molecular and genetic diagnostics projected for 2026. We analyze the key drivers behind this trend and outline how MedTech and IVD companies can create value in high-growth areas like oncology, infectious disease, personalized medicine, and the development of integrated data platforms that provide actionable clinical insights. - Why is diagnostic spending shifting dramatically towards molecular and genetic tests by 2026? - What are the primary drivers making advanced genomic testing more accessible? - How can MedTech companies create value in oncology beyond traditional diagnostics? - What is the critical role of point-of-care molecular testing in managing infectious diseases? - Why are integrated data platforms and AI becoming essential for the next wave of diagnostics? - How does personalized medicine change the strategy for diagnostic companies? - What are the opportunities in companion diagnostics and liquid biopsies? - Is your company prepared to navigate the regulatory complexities of these advanced IVDs? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, helping you access over 30 global markets. We leverage advanced AI and data tools to develop efficient regulatory strategies, compile technical dossiers, and streamline submissions, minimizing costs and accelerating your time to market. Whether you're a startup or a multinational, our local experts provide the support needed to navigate complex international requirements for cutting-edge diagnostics. Contact us at [email protected], visit https://pureglobal.com/, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode examines the critical threat facing the U.S. diagnostics industry due to flawed implementation of the Protecting Access to Medicare Act (PAMA). We explore how skewed data collection has led to severe reimbursement cuts, disproportionately impacting smaller, innovative labs. We discuss the 2026 outlook, the looming risk of market consolidation, and how this environment stifles investment in new diagnostic technologies, potentially limiting patient access to care. - What is the Protecting Access to Medicare Act (PAMA) and why is it a threat to US labs? - How do reimbursement cuts disproportionately harm smaller, innovative diagnostics companies? - What is the significance of the 2026 deadline for Medicare lab payments? - Could ongoing payment pressure lead to mass consolidation in the diagnostics market? - How does this environment impact investment in new testing platforms? - What is the RESULTS Act and could it be a permanent solution? - What are the long-term risks to patient access to advanced diagnostics in the US? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with a unique blend of local expertise and advanced AI. We help you develop efficient regulatory strategies, leveraging your existing approvals to identify the best new markets for expansion. Our team uses powerful data tools to compile and submit technical dossiers, helping you navigate complex landscapes like the U.S. reimbursement system to bring your innovations to patients faster. For a smarter path to global market access, contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode forecasts the state of medical technology mergers and acquisitions for 2026. We analyze whether the industry will see a return to large, transformative deals driven by the need to fill portfolio gaps in diagnostics, structural heart, and workflow assets, or if valuation discipline and integration risks will ensure the market remains focused on smaller, more selective acquisitions. - Will 2026 mark the return of mega-mergers in the medical device industry? - What portfolio gaps are large medtech companies trying to fill? - Why are diagnostics and structural heart technologies so attractive for acquisition? - How do high valuations and integration risks impact M&A decisions? - What role will regulatory scrutiny play in future deals? - Are smaller 'tuck-in' acquisitions a safer bet for growth? - How can companies prepare their regulatory strategy for post-merger integration? Successful M&A is just the first step; integrating a new portfolio and achieving global market access is the next challenge. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, ensuring your expanded product line meets international compliance. Our experts develop efficient regulatory strategies and use advanced AI to compile technical dossiers, streamlining submissions across 30+ markets. Whether you're a startup or a multinational enterprise navigating post-acquisition complexities, we provide the local expertise and data tools to accelerate your global growth. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools at https://pureglobal.ai.

This episode explores the significant impact that rising tariffs and supply-chain nationalism are projected to have on the medical technology industry by 2026. We dissect the four primary strategic responses available to MedTech firms: relocating production, diversifying sourcing networks, increasing prices, or absorbing shrinking profit margins. The host explains how these choices will be influenced by device category, reimbursement landscapes, and specific geopolitical tensions, urging companies to proactively plan for a new era of manufacturing and market access. Key Questions: - What is “supply-chain nationalism” and why is it a major threat to MedTech? - By 2026, how will new tariffs disrupt established manufacturing models? - Is relocating production (reshoring) a viable option for most device manufacturers? - How can companies redesign sourcing networks to mitigate geopolitical risks? - Will healthcare systems accept price increases driven by supply chain costs? - What happens to innovation if companies are forced to absorb lower profit margins? - Which device categories are most vulnerable to these global shifts? Navigating the challenges of tariffs and supply chain realignment demands a proactive, global regulatory strategy. Pure Global helps MedTech and IVD companies navigate this complexity. Our experts develop efficient pathways for regulatory approval and market access in over 30 countries, using advanced AI to compile technical dossiers and monitor regulatory changes. Whether you're assessing new markets to diversify your footprint or ensuring continuous compliance amidst shifting trade policies, we provide the local expertise and data-driven tools to secure your global presence. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools at https://pureglobal.ai.

This episode examines the immense pressures facing medical device manufacturers from Europe's Medical Device Regulation (MDR) and In-Vitro Diagnostic Regulation (IVDR) leading up to 2026. We explore the two potential outcomes: widespread "portfolio pruning" and market consolidation due to high compliance costs and Notified Body bottlenecks, or the successful reduction of these pressures by regulators before essential devices are removed from the market. Key Questions: - What are the biggest challenges manufacturers face with the EU MDR and IVDR transition? - Why is the year 2026 so critical for the European MedTech market? - What is "portfolio pruning" and how could it affect patient care? - Will the shortage of Notified Bodies lead to a market crisis? - How are companies deciding which products to keep and which to discontinue? - Could MDR and IVDR compliance costs force smaller companies out of the market? - What steps can be taken to reduce the regulatory bottlenecks in Europe? - Is industry consolidation an inevitable outcome of these new regulations? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies navigating complex landscapes like Europe's MDR/IVDR transition. We combine local expertise with advanced AI to streamline global market access, developing efficient regulatory strategies and compiling technical dossiers. Whether you are managing portfolio decisions or seeking new market entry, our team can help. Visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai to accelerate your global reach.

This episode delves into the upcoming 2026 Medical Device User Fee Amendments (MDUFA VI) negotiations and their profound impact on the U.S. medtech landscape. We explore how these negotiations will influence FDA review predictability, staffing stability, and fee structures, and what this means for the strategic planning of medical device companies, particularly startups and smaller innovators. - What are the Medical Device User Fee Amendments (MDUFA)? - Why are the 2026 negotiations critical for medtech innovation? - How does FDA review predictability affect a small company's fundraising and launch schedule? - What is the link between user fees and FDA staffing challenges? - Will the new MDUFA fee structure help or hinder smaller medtech firms? - How should companies adjust their regulatory strategy in anticipation of MDUFA VI? - What performance goals will the industry push for in the next MDUFA cycle? Navigating the U.S. FDA and other global markets requires expert strategy. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, leveraging local expertise and advanced AI tools to streamline market access. From developing efficient regulatory strategies and pre-submission activities for the FDA to acting as your local representative in over 30 markets, we ensure you can launch and maintain your products efficiently. Our technology-driven approach enhances accuracy and speed, helping you stay ahead. Visit our website at https://pureglobal.com/, contact us at [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores the prediction that by 2026, the primary obstacle for AI medical devices will shift from technical validation to securing financial reimbursement. We discuss why clear payment pathways, understandable coding logic, and compelling health economic outcome evidence are becoming more critical than algorithmic accuracy for commercial success. This is a crucial look at the strategic planning required to navigate the evolving landscape of AI MedTech market access. Key Questions: - Why is technical accuracy no longer enough for AI medical device success? - What are the biggest reimbursement challenges facing AI MedTech in 2026? - How do payment pathways and coding logic determine commercial viability? - What kind of outcome evidence do health systems and payers actually require? - Is your AI device strategy prepared for the post-approval reimbursement bottleneck? - How can you build a reimbursement strategy from day one of product development? - What role does health economics play in market access for advanced AI tools? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We develop efficient pathways for regulatory approval and help you identify the best markets for expansion by leveraging your existing approvals. Our experts use advanced AI to compile and submit technical documents, ensuring you can navigate complex global requirements. Whether you're a startup or a multinational, we provide scalable solutions to get your innovation to market faster. Contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores the future of the diabetes technology market, examining the critical tension between rapid innovation and foundational regulatory challenges. We analyze whether the competitive landscape leading into 2026 will be defined more by exciting advancements like fully closed-loop systems and longer-wear sensors, or by persistent issues such as product recalls, complaint handling, and software reliability. We discuss how market leaders must master both cutting-edge development and stringent post-market compliance to succeed. Key Questions: - How are fully closed-loop artificial pancreas systems set to redefine diabetes care? - What makes longer-wear CGM sensors a major competitive battleground? - Why have recalls and complaint handling become such significant hurdles for leading MedTech firms? - Is software reliability the most critical, yet overlooked, factor in automated insulin delivery? - How can manufacturers balance groundbreaking innovation with the demands of global regulators? - What will separate the market leaders from the followers in the diabetes tech space by 2026? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, helping you navigate these complex challenges. Our experts develop efficient pathways for regulatory approval, using advanced AI to compile and submit technical dossiers for devices, including complex Software as a Medical Device (SaMD). We also manage post-market surveillance and continuous regulatory monitoring to ensure you not only enter the market but maintain your presence securely. Let us help you balance innovation with compliance. Contact Pure Global at [email protected], visit us at https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

This episode explores the transformative potential of AI-enabled imaging and ultrasound tools designed for non-experts, set to reshape diagnostics by 2026. We dissect the four emerging business models—hardware, workflow software (SaMD), remote interpretation, and population-scale screening—and analyze the unique global regulatory, data privacy, and market access challenges associated with each. Discover which strategies are best positioned to succeed in this new era of decentralized healthcare. Key Questions: - How will AI empower non-specialists to use advanced ultrasound and imaging tools by 2026? - What are the four primary business models emerging from this technology shift? - What specific regulatory hurdles exist for AI-enabled hardware versus Software as a Medical Device (SaMD)? - How do data privacy laws like GDPR and HIPAA impact remote interpretation services? - What are the unique market access challenges for population-scale screening programs? - Why is a unified global regulatory strategy essential for success in this new market? - Which business model is best positioned to capture value by navigating these complexities? Navigating the complex regulatory landscape for AI-driven medical devices is critical. Pure Global specializes in helping innovative MedTech and IVD companies commercialize their products globally. We develop efficient regulatory strategies for complex technologies like Software as a Medical Device (SaMD) and AI-enabled hardware, helping you overcome market access hurdles in over 30 countries. Our integrated approach combines local expertise with advanced AI tools to streamline technical dossier submission and ensure ongoing compliance. To accelerate your global expansion, contact Pure Global at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores the transformative shift in the surgical robotics market, predicting a move away from a single-player monopoly by 2026. We analyze the impact of new FDA-approved platforms from giants like Medtronic and Johnson & Johnson, the rise of specialization in fields such as orthopedics and cardiac surgery, and how competition is now being driven by factors like price, workflow efficiency in ambulatory surgical centers, and the integration of artificial intelligence. - Will the surgical robotics market remain dominated by one giant in 2026? - How are new FDA approvals for Medtronic’s Hugo and J&J’s Ottava changing the competitive landscape? - Is specialization in spine, cardiac, and microsurgery the new frontier for robotic platforms? - How do smaller, modular robots create new opportunities in ambulatory surgical centers (ASCs)? - What role does Artificial Intelligence (AI) play in differentiating the next generation of surgical robots? - Are high costs and complex training no longer significant barriers to robotic surgery adoption? - What does increased competition mean for innovation, hospital procurement, and patient care? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with local expertise and advanced AI tools. From developing regulatory strategy and compiling technical dossiers to acting as your in-country representative in over 30 markets, we accelerate your path to commercialization. Our AI and data tools offer powerful market research capabilities, helping you identify the best regions for expansion. Whether you are a startup or a multinational, Pure Global provides efficient, technology-driven solutions for your global ambitions. Contact us at [email protected], visit https://pureglobal.com/, or explore our FREE AI tools at https://pureglobal.ai/.

This episode examines how U.S. FDA regulations have repositioned cybersecurity as a core feature of medical devices. We discuss the impact of the Consolidated Appropriations Act of 2023 and the FDA's "Refuse to Accept" policy, exploring why a secure architecture, a Software Bill of Materials (SBOM), and robust incident response plans are now critical for regulatory approval, hospital trust, and commercial success heading into 2026. - What new authority did the FDA gain over medical device cybersecurity in 2023? - Why is a Software Bill of Materials (SBOM) now a mandatory part of FDA submissions? - How has "secure by design" shifted from a best practice to a regulatory necessity? - What are the essential components of a compliant post-market cybersecurity plan? - How will a device's security posture directly influence hospital purchasing decisions by 2026? - What is the FDA's "Refuse to Accept" policy for cybersecurity? - How can manufacturers prepare their technical dossiers for these new requirements? Pure Global offers end-to-end consulting for MedTech and IVD companies, helping you navigate complex regulatory landscapes like the FDA's new cybersecurity rules. Our experts develop efficient regulatory strategies and use advanced AI to compile and submit technical dossiers that meet these stringent new standards. We act as your local representative to ensure continuous compliance and monitor regulatory changes that could impact your market access. Let us help you get to market faster. Contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.